COVID 19: a clue from innate immunity

被引:123
作者
Birra, Domenico [1 ]
Benucci, Maurizio [2 ]
Landolfi, Luigi [3 ]
Merchionda, Anna [1 ]
Loi, Gabriella [1 ]
Amato, Patrizia [4 ]
Licata, Gaetano [5 ]
Quartuccio, Luca [6 ]
Triggiani, Massimo [7 ]
Moscato, Paolo [1 ]
机构
[1] Azienda Osped Univ San Giovanni di Dio & Ruggi DA, UOC Internal Med, Rheumatol Outpatients Unit, Via San Leonardo 1, Salerno, Italy
[2] S Giovanni di Dio Hosp, Rheumatol Unit, Florence, Italy
[3] Azienda Osped Univ San Giovanni di Dio & Ruggi DA, UOC Internal Med, Salerno, Italy
[4] ASL Salerno, SERT, Salerno, Italy
[5] Univ Campania Luigi Vanvitelli, Dermatol Unit, Naples, Italy
[6] Univ Udine, Dept Med DAME, ASUFC, Clin Rheumatol, Udine, Italy
[7] Univ Salerno, Div Allergy & Clin Immunol, Fisciano, Italy
关键词
COVID-19; Coronavirus; SARS; Innate immunity; TLR; Interferon; ACUTE RESPIRATORY SYNDROME; TOLL-LIKE RECEPTORS; CORONAVIRUS INFECTION; I INTERFERON; SARS; PROTECTION; RESPONSES; DISEASE; TRIF;
D O I
10.1007/s12026-020-09137-5
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The recent COVID-19 pandemic has had a significant impact on our lives and has rapidly expanded to reach more than 4 million cases worldwide by May 2020. These cases are characterized by extreme variability, from a mild or asymptomatic form lasting for a few days up to severe forms of interstitial pneumonia that may require ventilatory therapy and can lead to patient death. Several hypotheses have been drawn up to understand the role of the interaction between the infectious agent and the immune system in the development of the disease and the most severe forms; the role of the cytokine storm seems important. Innate immunity, as one of the first elements of guest interaction with different infectious agents, could play an important role in the development of the cytokine storm and be responsible for boosting more severe forms. Therefore, it seems important to study also this important arm of the immune system to adequately understand the pathogenesis of the disease. Research on this topic is also needed to develop therapeutic strategies for treatment of this disease.
引用
收藏
页码:161 / 168
页数:8
相关论文
共 66 条
[51]   Toll-like receptors and type I interferons [J].
Uematsu, Satoshi ;
Akira, Shizuo .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (21) :15319-15323
[52]   The induction of innate and adaptive immunity by biodegradable poly(γ-glutamic acid) nanoparticles via a TLR4 and MyD88 signaling pathway [J].
Uto, Tomofumi ;
Akagi, Takami ;
Yoshinaga, Keisuke ;
Toyama, Masaaki ;
Akashi, Mitsuru ;
Baba, Masanori .
BIOMATERIALS, 2011, 32 (22) :5206-5212
[53]   The Pathology and Pathogenesis of Experimental Severe Acute Respiratory Syndrome and Influenza in Animal Models [J].
van den Brand, J. M. A. ;
Haagmans, B. L. ;
van Riel, D. ;
Osterhaus, A. D. M. E. ;
Kuiken, T. .
JOURNAL OF COMPARATIVE PATHOLOGY, 2014, 151 (01) :83-112
[54]  
van Kraaij Tom DA, 2020, Eur J Case Rep Intern Med, V7, P001675, DOI 10.12890/2020_001675
[55]   Coronavirus Endoribonuclease and Deubiquitinating Interferon Antagonists Differentially Modulate the Host Response during Replication in Macrophages [J].
Volk, Aaron ;
Hackbart, Matthew ;
Deng, Xufang ;
Cruz-Pulido, Yazmin ;
O'Brien, Amornrat ;
Baker, Susan C. .
JOURNAL OF VIROLOGY, 2020, 94 (11)
[56]  
W-j G, 2020, N Engl J Med, V382, P1708, DOI [10.1056/NEJMoa2002032, DOI 10.1056/NEJMOA2002032]
[57]   Intravenous Anakinra for Macrophage Activation Syndrome May Hold Lessons for Treatment of Cytokine Storm in the Setting of Coronavirus Disease 2019 [J].
Wampler Muskardin, Theresa L. .
ACR OPEN RHEUMATOLOGY, 2020, 2 (05) :283-285
[58]   IL-6 may be a good biomarker for earlier detection of COVID-19 progression [J].
Wang, Changsong ;
Fei, Dongsheng ;
Li, Xueting ;
Zhao, Mingyan ;
Yu, Kaijiang .
INTENSIVE CARE MEDICINE, 2020, 46 (07) :1475-1476
[59]   A molecular arms race between host innate antiviral response and emerging human coronaviruses [J].
Wong, Lok-Yin Roy ;
Lui, Pak-Yin ;
Jin, Dong-Yan .
VIROLOGICA SINICA, 2016, 31 (01) :12-23
[60]   Effective treatment of severe COVID-19 patients with tocilizumab [J].
Xu, Xiaoling ;
Han, Mingfeng ;
Li, Tiantian ;
Sun, Wei ;
Wang, Dongsheng ;
Fu, Binqing ;
Zhou, Yonggang ;
Zheng, Xiaohu ;
Yang, Yun ;
Li, Xiuyong ;
Zhang, Xiaohua ;
Pan, Aijun ;
Wei, Haiming .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2020, 117 (20) :10970-10975